Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Biogen Alzheimer drug...

    Biogen Alzheimer drug Aducanumab failure wipes USD 18 billion from market value

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-09-16T09:00:32+05:30  |  Updated On 16 Sept 2019 9:00 AM IST
    Biogen Alzheimer drug Aducanumab failure wipes USD 18 billion from market value

    Aducanumab's failure wiped out more than $18 billion of Biogen Inc's market value, as investors were betting on the treatment to buoy the drugmaker, which is mired in patent issues over its big-selling multiple sclerosis drug Tecfidera and possible competition to spinal muscular atrophy drug Spinraza.


    U.S: Biogen Inc and Eisai Co Ltd are abandoning two late-stage trials for their Alzheimer's treatment in a widely anticipated move that comes months after the companies scrapped trials of another drug for the memory-robbing disease.


    The companies said on Friday that the decision was based on the results of a review conducted by a data safety monitoring board, which recommended discontinuing the trials as benefits from the treatment, elenbecestat, did not outweigh its risks.


    Shares of Biogen were up 2.3% at $237.60 as some analysts said ending the trial would save the company costs associated with running it through its completion.


    "This was widely expected by the investment community, including ourselves, and amounts to a further step in the unwinding of Biogen's expensive, painful and ultimately fruitless investment in Alzheimer's disease drug development," SVB Leerink analyst Geoffrey Porges said.


    The companies in March ended two late-stage trials of another experimental Alzheimer's drug, aducanumab.


    Aducanumab's failure wiped out more than $18 billion of Biogen's market value, as investors were betting on the treatment to buoy the drugmaker, which is mired in patent issues over its big-selling multiple sclerosis drug Tecfidera and possible competition to spinal muscular atrophy drug Spinraza.


    Elenbecestat belongs to a class of drugs called beta-amyloid cleaving enzyme (BACE) inhibitors, which act by inhibiting the production of amyloid beta - a protein believed to be a major cause of Alzheimer's disease.


    However, drugmakers such as Amgen Inc and Novartis AG, Eli Lilly and Co and AstraZeneca Plc have all abandoned some of their BACE inhibitor trials earlier.


    While there may have been similar failures in other companies, as a percentage of one large company's value and its total R&D investment, it would be hard to find a bigger disappointment, Porges said.


    Biogen and Eisai said on Friday their latest decision does not impact their other Alzheimer's study testing experimental treatment, BAN2401, which belongs to a different drug class.


    By Manojna Maddipatla


    Read Also: Biogen announces $5 billion buyback days after shelving Alzheimers trials

    aducanumabAlzheimerBACEBAN2401BiogendrugmakerEisaiEli LillyGeoffrey PorgesManojna Maddipatlapharmapharma companypharma newsspinal muscular atrophyTecfideratrial failure
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok